# DEA Scheduling Synthetic Opioids: Regulatory Updates 2026

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/
> **Published:** 2026-03-10T00:34:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:59:44-04:00
> **Clinical Summary:** Explore DEA scheduling synthetic opioids and regulatory updates impacting cannabis clinicians and medical practice in 2026.

---

Policy WatchMarch 10, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.

Score 70Regulations.gov

[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011)

The DEA scheduled three synthetic opioids in Schedule I, establishing their legal status as controlled substances with no accepted medical use, relevant to cannabis clinicians evaluating alternative pain management options.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013)

This regulatory action schedules ethylphenidate as a controlled substance, which may indirectly affect cannabis clinicians treating ADHD patients who might otherwise consider cannabis as an alternative therapeutic option.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0013)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001)

The DEA temporarily scheduled two opioid analogs in Schedule I, establishing regulatory precedent for controlling novel synthetic drugs but having no direct impact on cannabis medical practice or patients.

[Read more →](https://www.regulations.gov/document/DEA-2024-0118-0001)

Score 70Regulations.gov
[Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001)

Regulatory Summary

DEA approval for controlled-biopharmaceutical importation enables cannabis-derived pharmaceutical products to enter the U.S. market, expanding clinician access to cannabis-based medicines and patient treatment options.

[Read more →](https://www.regulations.gov/document/DEA-2024-0112-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003)

Regulatory Summary

This action temporarily placed synthetic opioids in Schedule I, establishing a precedent for emergency scheduling of novel substances but does not directly impact cannabis clinical practice or patient access.

[Read more →](https://www.regulations.gov/document/DEA-2023-0147-0003)

Score 70Regulations.gov
[Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001)

Regulatory Summary

The DEA proposed rescheduling marijuana from Schedule I to Schedule III, potentially enabling [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and clinical use while reducing legal barriers for healthcare providers and patients seeking [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/).

[Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001)

Score 70Regulations.gov
[Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

This firearms regulation does not directly apply to cannabis clinicians or patients, as it addresses federal firearm dealer licensing requirements unrelated to cannabis medical practice or patient care.

[Read more →](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006)

Regulatory Summary

This DEA action schedules three synthetic opioids (etodesnitazene, N-pyrrolidino etonitazene, and protonitazene) as Schedule I controlled substances, with minimal direct relevance to cannabis clinical practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007)

Regulatory Summary

This action schedules three synthetic opioids as controlled substances, establishing regulatory precedent for substance classification but having no direct clinical impact on [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001)

Regulatory Summary

The DEA placed 2-Methyl AP-237, a synthetic opioid, into Schedule I, restricting its availability; this action has minimal direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001)

This DEA action schedules synthetic amphetamines as Schedule I controlled substances, having no direct relevance to cannabis medicine, clinicians, or patients.

[Read more →](https://www.regulations.gov/document/DEA-2023-0168-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004)

The DEA temporarily scheduled six synthetic cannabinoids as Schedule I controlled substances, restricting their legal use and potentially affecting [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) into [cannabinoid pharmacology](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/) and alternative treatment options.

[Read more →](https://www.regulations.gov/document/DEA-2023-0049-0004)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001)

Regulatory Summary

This item addresses Schedule I placement of ethylphenidate (a stimulant), which is not directly relevant to cannabis clinicians or patients as it involves a separate controlled substance outside cannabis therapeutics.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005)

Regulatory Summary

This DEA action schedules metonitazene as a controlled substance, establishing regulatory precedent for synthetic drug classification that may inform future cannabis scheduling reviews and clinical documentation requirements for practitioners.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0005)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004)

Regulatory Summary

The DEA temporarily scheduled five benzodiazepine analogs as Schedule I controlled substances, relevant to cannabis clinicians managing patients with anxiety or sleep disorders who might otherwise receive these medications as adjunctive treatments.

[Read more →](https://www.regulations.gov/document/DEA-2022-0145-0004)

Score 70Regulations.gov
[Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001)

Regulatory Summary

DEA Form 1224 permits biopharmaceutical research companies to legally import controlled substances, including cannabis, for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and development purposes.

[Read more →](https://www.regulations.gov/document/DEA-2023-0096-0001)

Score 55Regulations.gov
[Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001)

Regulatory Summary

This DEA import permit (2024-20083) authorizes controlled substance importation, potentially affecting cannabis clinicians’ and patients’ access to regulated cannabis-derived pharmaceuticals and research materials.

[Read more →](https://www.regulations.gov/document/DEA-2024-0111-0001)

Score 55Regulations.gov
[Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001)

Regulatory Summary

DEA registration 2024-20082 authorizes Cambridge Isotope as a controlled substance importer, potentially enabling research-grade cannabis or cannabinoid isotope standards for clinical studies and analytical testing.

[Read more →](https://www.regulations.gov/document/DEA-2024-0110-0001)

Score 55Regulations.gov
[Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045)

CMS updates Medicare/Medicaid physician payment policies and coverage rules for calendar year 2025, potentially affecting reimbursement rates and coverage determinations for cannabis-related medical services under Part B.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0045)

Score 55Regulations.gov
[Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)](https://www.regulations.gov/document/CMS-2024-0256-0001)

This CMS proposed rule updates Medicare/Medicaid payment policies and coverage for Part B services; cannabis remains federally prohibited, making this rule indirectly relevant only if state-legal cannabis treatments gain future Medicare coverage consideration.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0001)

Digest-Level Clinical Commentary

 Dr. Caplan’s Take
 Clinical Reflection

Item 6, the rescheduling of marijuana, represents the most clinically relevant development in this digest, as it signals potential federal recognition of cannabis’s medical utility and could enable the robust clinical research and pharmaceutical standardization that my specialty currently lacks. The preponderance of other items addressing synthetic opioids, stimulants, and benzodiazepines underscores a broader policy focus on novel psychoactive substances, which contextualizes cannabis rescheduling within a larger effort to address emerging drug threats while potentially creating regulatory space for evidence-based cannabis therapeutics. As a cannabis medicine specialist, I anticipate that rescheduling could facilitate the kind of rigorous pharmacokinetic studies, drug-drug interaction research, and prospective clinical trials that would substantially elevate the scientific foundation of my practice beyond its current reliance on

 Clinical Perspective

Clinical Perspective

These regulatory actions predominantly reflect ongoing efforts to control emerging synthetic opioids and designer drugs that have proliferated in illicit drug markets, particularly nitazene analogs and synthetic cannabinoids that pose significant public health risks. The repeated scheduling actions suggest a reactive regulatory approach to chemical modifications that circumvent existing controlled substance laws, creating challenges for clinical management of both acute intoxications and substance use disorders involving these novel compounds. From a clinical standpoint, these evolving drug landscapes necessitate enhanced toxicology screening capabilities and provider education regarding the pharmacology and toxidrome presentation of newly scheduled substances.

Controlled Substances SchedulingDEA RegulationsDrug EnforcementOpioid AnalogsSynthetic Drugs

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

 [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+March+10%2C+2026+%40drcaplan&url=)
 [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)
 [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+March+10%2C+2026+--+via+%40drcaplan.bsky.social+)
 [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)
 [📝 Read more on Substack](https://substack.com/@doctorapproved)
 [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)
 

 Related Articles

- [Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026](https://cedclinic.com/daily-digest-last-9-hours-stroke-risk-from-recreational-drugs-and-dea-scheduling-actions-march-08-2026/)

- [Firefighters are a step closer to being able to use medical cannabis – WMAR](https://cedclinic.com/medical-cannabis-firefighters-access-update/)

- [Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds](https://cedclinic.com/cbd-cbg-fatty-liver-disease-research/)

Further Reading
CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/)
Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/)
CED Clinic Blog[Smart Cannabis Dosing](https://cedclinic.com/smart-cannabis-dosing/)

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Policy Watch: 26 Regulatory Updates — March 08, 2026](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/)

Review the latest 26 regulatory updates prior to March 10, 2026, including controlled substances and cannabis-related policies.

[Read More](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/)

[Policy Watch: 25 Regulatory Updates — March 12, 2026](https://cedclinic.com/dea-scheduling-synthetic-drugs-march-12-2026/)

Stay informed on the 25 regulatory updates following March 10, 2026, with insights on synthetic opioids and cannabis regulations.

[Explore Updates](https://cedclinic.com/dea-scheduling-synthetic-drugs-march-12-2026/)

[Policy Watch: 20 Regulatory Updates — March 11, 2026](https://cedclinic.com/dea-marijuana-rescheduling-regulatory-updates-2026/)

Discover the 20 regulatory updates from March 11, 2026, focusing on controlled substances and implications for cannabis clinicians.

[Learn More](https://cedclinic.com/dea-marijuana-rescheduling-regulatory-updates-2026/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).